Literature DB >> 11918705

Expression of stress-induced MHC class I related chain molecules on human melanoma.

Claudia S Vetter1, Veronika Groh, Per thor Straten, Thomas Spies, Eva-B Bröcker, Jürgen C Becker.   

Abstract

Cellular immune responses to melanoma are tightly regulated and include specific T cell responses to self antigens such as Mart-1 and gp100. Thus, additional signals apart from those mediated by the T cell receptor are needed to ensure T cell activation. Recently, the stress inducible major histocompatibility complex molecules, MHC class I related chain, were identified as an activator of both natural killer and T cells via interaction with their receptor NKG2D. Herein, we report the expression of MIC in 31 of 40 primary cutaneous melanomas and in 13 of 20 metastatic lesions. Moreover, lymphocytes infiltrating the tumor were found to express NKG2D. Detailed analysis identified both CD3+ T cells as well as CD56+ natural killer cells contributing to this NKG2D+ tumor infiltrating lymphocyte population present.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11918705     DOI: 10.1046/j.1523-1747.2002.01700.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  54 in total

Review 1.  Effect of NKG2D ligand expression on host immune responses.

Authors:  Marine Champsaur; Lewis L Lanier
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

Review 2.  Mucosal T lymphocytes--peacekeepers and warriors.

Authors:  Hilde Cheroutre; Mitchell Kronenberg
Journal:  Springer Semin Immunopathol       Date:  2005-06-02

3.  NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors.

Authors:  Claire Godbersen; Tiffany A Coupet; Amelia M Huehls; Tong Zhang; Michael B Battles; Jan L Fisher; Marc S Ernstoff; Charles L Sentman
Journal:  Mol Cancer Ther       Date:  2017-05-12       Impact factor: 6.261

Review 4.  Recognition of tumors by the innate immune system and natural killer cells.

Authors:  Assaf Marcus; Benjamin G Gowen; Thornton W Thompson; Alexandre Iannello; Michele Ardolino; Weiwen Deng; Lin Wang; Nataliya Shifrin; David H Raulet
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

5.  Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer.

Authors:  Xiaohui Duan; Langmei Deng; Xiong Chen; Yebin Lu; Qi Zhang; Kejing Zhang; Yongjun Hu; Jie Zeng; Weijia Sun
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

6.  Ectopically expressed human tumor biomarker MutS homologue 2 is a novel endogenous ligand that is recognized by human γδ T cells to induce innate anti-tumor/virus immunity.

Authors:  Yumei Dai; Hui Chen; Chen Mo; Lianxian Cui; Wei He
Journal:  J Biol Chem       Date:  2012-03-20       Impact factor: 5.157

7.  Large scale ex vivo expansion of clinical-grade effector cells for adoptive immunotherapy.

Authors:  Huiying Yu; Wei Chen; Changling Li; Di Lin; Junde Liu; Zien Yang; Jingang Yang; Yinghui Sun; Dongchu Ma
Journal:  Exp Ther Med       Date:  2017-09-29       Impact factor: 2.447

8.  Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation.

Authors:  Jennifer D Wu; Catherine L Atteridge; Xuanjun Wang; Tsukasa Seya; Stephen R Plymate
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

9.  Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer.

Authors:  Jennifer D Wu; Lily M Higgins; Alexander Steinle; David Cosman; Kathy Haugk; Stephen R Plymate
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

10.  An six-amino acid motif in the alpha3 domain of MICA is the cancer therapeutic target to inhibit shedding.

Authors:  Xuanjun Wang; Ashley D Lundgren; Pragya Singh; David R Goodlett; Stephen R Plymate; Jennifer D Wu
Journal:  Biochem Biophys Res Commun       Date:  2009-07-16       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.